Mittwoch, 9. Oktober 2013

Artemisinin derivative artesunate induces radiosensitivity in cervical cancer cells in vitro and in vivo

Radiation Oncology | Full text | Artemisinin derivative artesunate induces radiosensitivity in cervical cancer cells in vitro and in vivo

Radiation Oncology 2014, 9:84  Published: 25 March 2014

Objective

Cervical cancer is the third most common type of cancer in women worldwide and radiotherapy remains its predominant therapeutic treatment. Artesunate (ART), a derivative of artemisinin, has shown radiosensitization effect in previous studies. However, such effects of ART have not yet been revealed for cervical cancer cells...






Dienstag, 8. Oktober 2013

Oral Artesunate Therapy for Colorectal Cancer

Cheap anti-malaria drug shows promise against colorectal cancer

A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer

Medical experts say a common malaria drug could have a significant impact on colorectal cancer providing a cheap adjunct to current expensive chemotherapy
November 18 2014



Cheap anti-malaria drug shows promise against colorectal cancer

"The survival beyond 2 years in the artesunate group was estimated at 91% whilst surviving the first recurrence of cancer in the placebo group was only 57%."


Fig. 4.
Survival recurrence curves predicted by Cox proportional hazards model. Patient CRC21 was assumed to be missing completely at random (please see Supplementary Table 1 for a full sensitivity analysis). In the placebo group 2 patients died within a year (108, 170) days leaving 10 (83%) in the study, another 2 within the next year (383, 663 days) leaving 8 (66%) in the study and the other two died within the third year of the follow up (749 and 990, respectively) leaving 50% patients beyond the third year. The only death in the artesunate group happened after 552 days leaving 9 patients (90%) surviving beyond the third year. These crude estimates support the estimates from the data above.


A Randomised, Double Blind, Placebo-Controlled Pilot Study of Oral Artesunate Therapy for Colorectal Cancer